#United States #Inc. #Boston Scientific #Alameda #Penumbra #thrombectomy

Penumbra, Inc. Reports Strong Financial Performance for Q3 2026

In a recent announcement, Penumbra, Inc. (NYSE: PEN), the global leader in thrombectomy solutions, revealed its financial performance for the third quarter of 2026, marking an extraordinary achievement in its operational metrics. The company reported revenue of $410.1 million for the quarter ending September 30, demonstrating a substantial growth of 15.6% compared to the previous year. This growth can be primarily attributed to an 18.1% increase in global thrombectomy revenue, reaching $279.2 million.

Strong Revenue Growth in Key Segments

Penumbra's performance was particularly impressive in the U.S. market, where vascular thromboembolism (VTE) revenue surged by 26.0%, showcasing the growing demand for advanced medical solutions. Furthermore, the company's global embolization and access revenue grew by 10.8%, totaling $131.0 million. Notably, U.S. neuro revenue also saw a significant uptick of 19.3% to $77.9 million. The company's gross profit margin was recorded at 68.3%, reflecting a slight improvement of 0.5% from the previous year.

Operational Insights and Expenses

Operating expenses for the quarter amounted to $229.6 million, comprising $25.4 million for research and development (R&D) and $204.2 million for sales, general, and administrative expenses (SGA). This figure includes $7.1 million associated with acquisition-related expenses due to the ongoing acquisition by Boston Scientific Corporation. Penumbra reported an operating income of $50.7 million, leading to a net income of $42.3 million for the quarter, which highlights the company's capability to remain profitable while investing in growth and innovation.

Outlook Amid Acquisition Process

Looking ahead, Penumbra has chosen not to provide financial guidance for the remainder of 2026, mainly due to the pending acquisition by Boston Scientific Corporation (NYSE: BSX). This strategic move indicates the company’s focus on integrating operations and aligning its business model with future objectives.

Penumbra, Inc. has built a reputation for its cutting-edge technologies aimed at treating complex medical conditions such as ischemic strokes and venous thromboembolism, including critical cases of acute limb ischemia and pulmonary embolism. Their innovative computer-assisted vacuum thrombectomy (CAVT) system is designed to remove blood clots efficiently, enhancing patient care across over 100 countries.

Conclusion

As Penumbra continues to navigate through these transformative times, its commitment to improving healthcare outcomes remains undeterred. The latest financial results not only illustrate the company's robust performance but also reinforce its leadership position in the thrombectomy market. The anticipation surrounding the acquisition adds a layer of excitement and expectation for the future developments in the company’s journey.

For more information about Penumbra, visit their official website at penumbrainc.com and follow them on social media platforms like Instagram, LinkedIn, and X.